V. Resta

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status

C. Ficorella, K. Cannita, A. Tessitore, 2022, Cancers.

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis

E. Ricevuto, C. Ficorella, K. Cannita, 2017, Oncotarget.

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations

E. Ricevuto, C. Ficorella, K. Cannita, 2018, Oncotarget.

The Sentinel Lymph Node in T1N0 Breast Cancer

G. De Rubeis, A. Bafile, V. Resta, 2000, Tumori.